FDA and EMA Accept Tebentafusp Applications for Metastatic Uveal Melanoma
Source: OncLive, August 2021
The FDA and the European Medicines Agency (EMA) have accepted applications seeking the approval of tebentafusp (IMCgp100) for use in the treatment of adult patients with HLA-A*02:01–positive metastatic uveal melanoma.1
In the United States, the regulatory agency has granted priority review to the biologics license application for the agent.
